Kevin M. Flanigan, MD :: Nationwide Children’s Hospital, Columbus, Ohio

Kevin M. Flanigan, MD

Kevin M. Flanigan, MD Best Doctors 2011-2012

Center for Gene Therapy
Principal Investigator

Kevin Flanigan Lab
Principal Investigator

Neurology
Physician Team

Neurology Residency
Faculty

Neuromuscular Disorders
Physician Team

Neuromuscular Genetic Therapeutics Fellowship
Program Director

Neurosciences
Physician Team

Contact Information

Neurology
700 Children's Dr
Columbus, OH 43205 [ map ]
PH: (614) 722-5615
FX: (614) 722-3273
E-mail Me
The Research Institute at Nationwide Children's Hospital
700 Childrens Drive
Columbus, OH 43205 [ map ]
PH: (614) 722.5615
FX: (614) 722.3273

Location Information for Patients

Main Campus
Westerville Surgery Center

Biography

Kevin M. Flanigan, MD, is an attending neurologist at Nationwide Children’s and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine. Certified by the American Board of Psychiatry and Neurology, Dr. Flanigan is a principal investigator in the Center for Gene Therapy in The Research Institute at Nationwide Children’s, and a leading expert in neuromuscular disorders. His primary research interest is in the genetic and molecular characterization of inherited neuromuscular diseases, and the development of therapies directed toward these diseases. A major focus of his laboratory concerns genotype/phenotype correlation in, with the intention of increasing our understanding of the pathogenesis in this disease and translating this understanding into improved therapies. Dr. Flanigan is named among the “Best Doctors in America.”

Gender:

  • Male

Languages Spoken:

  • English

Research Interests

Research Center:

Areas of Interest:

  • The Flanigan Lab focuses on the genetic and molecular characterization of inherited neuromuscular diseases, and toward the development of therapies directed toward these diseases. A major focus of the laboratory concerns genotype/phenotype correlation in dystrophinopathies (Duchenne and Becker Muscular Dystrophy), with the intention of increasing our understanding of the pathogenesis in this disease and translating this understanding into improved therapies. For example, studies of rare patient mutations have generated hypotheses regarding function of the dystrophin protein, now under study in the lab. Other projects in the lab are dedicated to the molecular characterization of both rare and common neurologic syndromes. One such disorder is giant axonal neuropathy, a rare inherited disorder characterized by degeneration of peripheral nerves with giant axonal swelling full of disorganized neurofilaments. Recent disease gene mapping projects have characterized gene loci responsible for an uncommon form of congenital muscular dystrophy, a novel form of hereditary spastic paraplegia, and a novel form of juvenile recessive amyotrophic lateral sclerosis. The goal of the laboratory is a better understanding and improved treatment of these and related diseases. Lab Web Site: http://www.nationwidechildrens.org/flanigan-lab

Education and Training

Medical School

  • Rush Medical College
    Date Completed: 06/09/1990

Internship

  • University of Michigan Health System
    Date Completed: 07/30/1991

Residency

  • Johns Hopkins Hospital
    Date Completed: 06/30/1994

Fellowship

  • Johns Hopkins Hospital
    Date Completed: 06/30/1995

Fellowship

  • University of Utah Medical School
    Date Completed: 06/30/1997

Department:

  • Pediatrics

Section:

  • Neurology

Specialty:

  • Neurology
  • Neuromuscular Medicine

Date of Appointment at Nationwide Children’s Hospital:

  • 01/29/2010

Professional Experience

2009–present

  • Principal Investigator, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH

2007–2009

  • Adjunct Associate Professor, University of Utah School of Medicine, Department of Pediatrics, Salt Lake City, UT

2007–2009

  • Adjunct Associate Professor, University of Utah School of Medicine, Department of Pathology, Salt Lake City, UT

2006–2007

  • Visiting Researcher, INSERM Unit 582; Institut de Myologie; l’Hopital Pitie-Salpetriere, Paris, France

2005–2009

  • Adjunct Associate Professor, University of Utah, Department of Human Genetics, Salt Lake City, UT

2005–2009

  • Associate Professor, University of Utah School of Medicine, Department of Neurology, Salt Lake City, UT

2001–2005

  • Adjunct Assistant Professor, University of Utah, Department of Human Genetics, Salt Lake City, UT

2000–2007

  • Adjunct Assistant Professor, University of Utah School of Medicine, Department of Pediatrics, Salt Lake City, UT

1999–2004

  • Assistant Professor, University of Utah School of Medicine, Department of Neurology, Salt Lake City, UT

1998–2007

  • Adjunct Assistant Professor, University of Utah School of Medicine, Department of Pathology, Salt Lake City, UT

1997–1998

  • Research Assistant Professor, University of Utah School of Medicine, Department of Neurology, Salt Lake City, UT

1996–1998

  • Limited Term Instructor, University of Utah School of Medicine, Department of Pathology, Salt Lake City, UT

1995–1997

  • Limited Term Instructor, University of Utah School of Medicine, Department of Neurology, Salt Lake City, UT

Publications

  • Vulin,Adeline; Wein,Nicolas; Strandjord,Dana,M; Johnson,Eric,K; Findlay,Andrew,R; Maiti,Baijayanta; Howard,Michael,T; Kaminoh,Yuuki,J; Taylor,Laura,E; Simmons,Tabatha,R; Ray,Will,C; Montanaro,Federica; Ervasti,Jim,M; Flanigan,Kevin,M. 2014. The ZZ Domain of Dystrophin in DMD: Making Sense of Missense Mutations.  HUMAN MUTATION. Vol. 35, no. 2. (February): 257-264.
  • Martin,Paul,T; Golden,Bethannie; Okerblom,Jonathan; Camboni,Marybeth; Chandrasekharan,Kumaran; Xu,Rui; Varki,Ajit; Flanigan,Kevin,M; Kornegay,Joe,N. 2014. A Comparative Study of N-glycolylneuraminic Acid (Neu5Gc) and Cytotoxic T Cell (CT) Carbohydrate Expression in Normal and Dystrophin-Deficient Dog and Human Skeletal Muscle.  PloS one. Vol. 9, no. 2. (January): ee88226.
  • Flanigan,Kevin,M; Voit,Thomas; Rosales,Xiomara,Q; Servais,Laurent; Kraus,John,E; Wardell,Claire; Morgan,Allison; Dorricott,Susie; Nakielny,Joanna; Quarcoo,Naashika; Liefaard,Lia; Drury,Tom; Campion,Giles; Wright,Padraig. 2014. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial.  Neuromuscular disorders. Vol. 24, no. 1. (January): 16-24.
  • Finkel,Richard,S; Flanigan,Kevin,M; Wong,Brenda; Boennemann,Carsten; Sampson,Jacinda; Sweeney,H,Lee; Reha,Allen; Northcutt,Valerie,J; Elfring,Gary; Barth,Jay; Peltz,Stuart,W. 2013. Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy.  PLOS ONE. Vol. 8, no. 12. (December): ee81302.
  • Butterfield,Russell,J; Foley,A,Reghan; Dastgir,Jahannaz; Asman,Stephanie; Dunn,Diane,M; Zou,Yaqun; Hu,Ying; Donkervoort,Sandra; Flanigan,Kevin,M; Swoboda,Kathryn,J; Winder,Thomas,L; Weiss,Robert,B; Boennemann,Carsten,G. 2013. Position of Glycine Substitutions in the Triple Helix of COL6A1, COL6A2, and COL6A3 is Correlated with Severity and Mode of Inheritance in Collagen VI Myopathies.  HUMAN MUTATION. Vol. 34, no. 11. (November): 1558-1567.
  • Bladen,Catherine,L; Rafferty,Karen; Straub,Volker; Monges,Soledad; Moresco,Angelica; Dawkins,Hugh; Roy,Anna; Chamova,Teodora; Guergueltcheva,Velina; Korngut,Lawrence; Campbell,Craig; Dai,Yi; Barisic,Nina; Kos,Tea; Brabec,Petr; Rahbek,Jes; Lahdetie,Jaana; Tuffery-Giraud,Sylvie; Claustres,Mireille; Leturcq,France; Ben Yaou,Rabah; Walter,Maggie,C; Schreiber,Olivia; Karcagi,Veronika; Herczegfalvi,Agnes; Viswanathan,Venkatarman; Bayat,Farhad; Sarmiento,Isis,de la Caridad Guerrero; Ambrosini,Anna; Ceradini,Francesca; Kimura,En; van den Bergen,Janneke,C; Rodrigues,Miriam; Roxburgh,Richard; Lusakowska,Anna; Oliveira,Jorge; Santos,Rosario; Neagu,Elena; Butoianu,Niculina; Artemieva,Svetlana; Rasic,Vedrana,Milic; Posada,Manuel; Palau,Francesc; Lindvall,Bjorn; Bloetzer,Clemens; Karaduman,Ayse; Topaloglu,Haluk; Inal,Serap; Oflazer,Piraye; Stringer,Angela; Shatillo,Andriy,V; Martin,Ann,S; Peay,Holly; Flanigan,Kevin,M; Salgado,David; von Rekowski,Brigitta; Lynn,Stephen; Heslop,Emma; Gainotti,Sabina; Taruscio,Domenica; Kirschner,Jan; Verschuuren,Jan; Bushby,Kate; Beroud,Christophe; Lochmueller,Hanns. 2013. The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia.  HUMAN MUTATION. Vol. 34, no. 11. (November): 1449-1457.
  • Thrush,Philip,T; Edward,Neeraj; Flanigan,Kevin,M; Mendell,Jerry,R; Allen,Hugh,D. 2013. Precordial R Wave Height Does Not Correlate with Echocardiographic Findings in Boys with Duchenne Muscular Dystrophy.  CONGENITAL HEART DISEASE. Vol. 8, no. 6. (November): 561-567.
  • Mendell,Jerry,R; Rodino-Klapac,Louise,R; Sahenk,Zarife; Roush,Kandice; Bird,Loren; Lowes,Linda,P; Alfano,Lindsay; Gomez,Ann,Maria; Lewis,Sarah; Kota,Janaiah; Malik,Vinod; Shontz,Kim; Walker,Christopher,M; Flanigan,Kevin,M; Corridore,Marco; Kean,John,R; Allen,Hugh,D; Shilling,Chris; Melia,Kathleen,R; Sazani,Peter; Saoud,Jay,B; Kaye,Edward,M. 2013. Eteplirsen for the Treatment of Duchenne Muscular Dystrophy.  ANNALS OF NEUROLOGY. Vol. 74, no. 5. (November): 637-647.
  • Flanigan,Kevin,M; Campbell,Katie; Viollet,Laurence; Wang,Wei; Gomez,Ana,Maria; Walker,Christopher,M; Mendell,Jerry,R. 2013. Anti-Dystrophin T Cell Responses in Duchenne Muscular Dystrophy: Prevalence and a Glucocorticoid Treatment Effect.  HUMAN GENE THERAPY. Vol. 24, no. 9. (September): 797-806.
  • Flanigan KM, Harper SQ. 2013. Facioscapulohumeral Muscular Dystrophy. In Muscle Disease: Pathology and Genetics. Edited by Goebel HH, Sewry CA, Weller RO. Oxford: Wiley.
  • Johnson,Eric,K; Li,Bin; Yoon,Jung,Hae; Flanigan,Kevin,M; Martin,Paul,T; Ervasti,James; Montanaro,Federica. 2013. Identification of New Dystroglycan Complexes in Skeletal Muscle.  PLOS ONE. Vol. 8, no. 8. (August): ee73224.
  • Connolly,Anne,M; Florence,Julaine,M; Cradock,Mary,M; Malkus,Elizabeth,C; Schierbecker,Jeanine,R; Siener,Catherine,A; Wulf,Charlie,O; Anand,Pallavi; Golumbek,Paul,T; Zaidman,Craig,M; Miller,J,Philip; Lowes,Linda,P; Alfano,Lindsay,N; Viollet-Callendret,Laurence; Flanigan,Kevin,M; Mendell,Jerry,R; McDonald,Craig,M; Goude,Erica; Johnson,Linda; Nicorici,Alina; Karachunski,Peter,I; Day,John,W; Dalton,Joline,C; Farber,Janey,M; Buser,Karen,K; Darras,Basil,T; Kang,Peter,B; Riley,Susan,O; Shriber,Elizabeth; Parad,Rebecca; Bushby,Kate; Eagle,Michelle. 2013. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.  NEUROMUSCULAR DISORDERS. Vol. 23, no. 7. (July): 529-539.
  • Flanigan,Kevin,M; Ceco,Ermelinda; Lamar,Kay-Marie; Kaminoh,Yuuki; Dunn,Diane,M; Mendell,Jerry,R; King,Wendy,M; Pestronk,Alan; Florence,Julaine,M; Mathews,Katherine,D; Finkel,Richard,S; Swoboda,Kathryn,J; Gappmaier,Eduard; Howard,Michael,T; Day,John,W; McDonald,Craig; McNally,Elizabeth,M; Weiss,Robert,B. 2013. LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy.  ANNALS OF NEUROLOGY. Vol. 73, no. 4. (April): 481-488.
  • Alfano,Lindsay,N; Lowes,Linda,P; Flanigan,Kevin,M; Mendell,Jerry,R. 2013. Correlation of knee strength to functional outcomes in becker muscular dystrophy.  MUSCLE & NERVE. Vol. 47, no. 4. (April): 550-554.
  • Flanigan,Kevin,M; Wein,Nicolas; Gurvich,Olga,L; Howard,Michael,T; Weiss,Robert,B. 2013. Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2.  Neuromuscular disorders. Vol. 23, no. 2. (February): 192-?.
  • Findlay,Andrew,R; Lewis,Sarah; Sahenk,Zarife; Flanigan,Kevin,M. 2013. Camptocormia as a late presentation in a manifesting carrier of duchenne muscular dystrophy.  MUSCLE & NERVE. Vol. 47, no. 1. (January): 124-127.
  • Allen HA, Mendell JR, Flanigan KM, Hoffman TM. 2013. The Heart in Muscular Dystrophies. In Moss and Adams’ Heart Disease in Infants, Children, and Adolescents, 8th edition. Edited by Allen HA, Shaddy RE, Driscoll DJ, Feltes TF. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins.
  • Allen,Hugh,D; Flanigan,Kevin,M; Thrush,Philip,T; Dvorchik,Igor; Yin,Han; Canter,Charles; Connolly,Anne,M; Parrish,Mark; McDonald,Craig,M; Braunlin,Elizabeth; Colan,Steven,D; Day,John; Darras,Basil; Mendell,Jerry,R. 2013. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.  PLoS currents. Vol. 5, no. January: eonline.
  • Lowes,Linda,P; Alfano,Lindsay,N; Yetter,Brent,A; Worthen-Chaudhari,Lise; Hinchman,William; Savage,Jordan; Samona,Patrick; Flanigan,Kevin,M; Mendell,Jerry,R. 2013. Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathy.  PLoS currents. Vol. 5, no. January: eonline.
  • Allen,Hugh,D; Thrush,Philip,T; Hoffman,Timothy,M; Flanigan,Kevin,M; Mendell,Jerry,R. 2012. Cardiac Management in Neuromuscular Diseases.  PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA. Vol. 23, no. 4. (November): 855-?.
  • Taylor,L,E; Kaminoh,Y,J; Rodesch,C,K; Flanigan,K,M. 2012. Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens.  NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. Vol. 38, no. 6. (October): 591-601.
  • Flanigan,Kevin,M. 2012. The Muscular Dystrophies.  SEMINARS IN NEUROLOGY. Vol. 32, no. 3. (July): 255-263.
  • Wallace,Lindsay,M; Liu,Jian; Domire,Jacqueline,S; Garwick-Coppens,Sara,E; Guckes,Susan,M; Mendell,Jerry,R; Flanigan,Kevin,M; Harper,Scott,Q. 2012. RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy.  MOLECULAR THERAPY. Vol. 20, no. 7. (July): 1417-1423.
  • Viollet,Laurence; Thrush,Philip,T; Flanigan,Kevin,M; Mendell,Jerry,R; Allen,Hugh,D. 2012. Effects of Angiotensin-Converting Enzyme Inhibitors and/or Beta Blockers on the Cardiomyopathy in Duchenne Muscular Dystrophy.  AMERICAN JOURNAL OF CARDIOLOGY. Vol. 110, no. 1. (July): 98-102.
  • Mendell,Jerry,R; Shilling,Chris; Leslie,Nancy,D; Flanigan,Kevin,M; Al-Dahhak,Roula; Gastier-Foster,Julie; Kneile,Kelley; Dunn,Diane,M; Duval,Brett; Aoyagi,Alexander; Hamil,Cindy; Mahmoud,Maha; Roush,Kandice; Bird,Lauren; Rankin,Chelsea; Lilly,Heather; Street,Natalie; Chandrasekar,Ram; Weiss,Robert,B. 2012. Evidence-Based Path to Newborn Screening for Duchenne Muscular Dystrophy.  ANNALS OF NEUROLOGY. Vol. 71, no. 3. (March): 304-313.
  • Kornegay,Joe,N; Bogan,Janet,R; Bogan,Daniel,J; Childers,Martin,K; Li,Juan; Nghiem,Peter; Detwiler,David,A; Larsen,C,Aaron; Grange,Robert,W; Bhavaraju-Sanka,Ratna,K; Tou,Sandra; Keene,Bruce,P; Howard,James,F; Wang,Jiahui; Fan,Zheng; Schatzberg,Scott,J; Styner,Martin,A; Flanigan,Kevin,M; Xiao,Xiao; Hoffman,Eric,P. 2012. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.  MAMMALIAN GENOME. Vol. 23, no. 1-2. (February): 85-108.
  • Lowes,Linda,Pax; Alfano,Lindsay; Viollet,Laurence; Rosales,Xiomara,Quintero; Sahenk,Zarife; Kaspar,Brian,K; Clark,K,Reed; Flanigan,Kevin,M; Mendell,Jerry,R; McDermott,Michael,P. 2012. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.  MUSCLE & NERVE. Vol. 45, no. 2. (February): 163-168.
  • Flanigan,Kevin,M; Dunn,Diane; Larsen,C,Aaron; Medne,Livija; Boennemann,Carsten,B; Weiss,Robert,B. 2011. BECKER MUSCULAR DYSTROPHY DUE TO AN INVERSION OF EXONS 23 AND 24 OF THE DMD GENE.  MUSCLE & NERVE. Vol. 44, no. 5. (November): 822-825.
  • Schenkenberg,T; Foster,N,L; Bromberg,M,B; Dewitt,L,D; Flanigan,K,M. 2011. Neurology Academic Advisory Committee A strategy for faculty retention and advancement.  NEUROLOGY. Vol. 77, no. 7. (August): 684-690.
  • Flanigan,Kevin,M; Dunn,Diane,M; von Niederhausern,Andrew; Soltanzadeh,Payam; Howard,Michael,T; Sampson,Jacinda,B; Swoboda,Kathryn,J; Bromberg,Mark,B; Mendell,Jerry,R; Taylor,Laura,E; Anderson,Christine,B; Pestronk,Alan; Florence,Julaine,M; Connolly,Anne,M; Mathews,Katherine,D; Wong,Brenda; Finkel,Richard,S; Bonnemann,Carsten,G; Day,John,W; McDonald,Craig; Weiss,Robert,B. 2011. Nonsense Mutation-Associated Becker Muscular Dystrophy: Interplay Between Exon Definition and Splicing Regulatory Elements within the DMD Gene.  HUMAN MUTATION. Vol. 32, no. 3. (March): 299-308.
  • Mendell JR; Rodino-Klapac LR; Rosales XQ; Coley BD; Galloway G; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Taylor LE; Flanigan KM; Gastier-Foster JM; Astbury C; Kota J; Sahenk Z; Walker CM; Clark KR. 2010. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.  Annals Of Neurology. Vol. 68, no. 5. (November): e629.
  • Soltanzadeh P; Friez MJ; Dunn D; von Niederhausern A; Gurvich OL; Swoboda KJ; Sampson JB; Pestronk A; Connolly AM; Florence JM; Finkel RS; Bönnemann CG; Medne L; Mendell JR; Mathews KD; Wong BL; Sussman MD; Zonana J; Kovak K; Gospe SM Jr; Gappmaier E; Taylor LE; Howard MT; Weiss RB; Flanigan KM. 2010. Clinical and genetic characterization of manifesting carriers of DMD mutations.  Neuromuscular Disorders: NMD. Vol. 20, no. 8. (August): e499.
  • Malik V; Rodino-Klapac LR; Viollet L; Wall C; King W; Al-Dahhak R; Lewis S; Shilling CJ; Kota J; Serrano-Munuera C; Hayes J; Mahan JD; Campbell KJ; Banwell B; Dasouki M; Watts V; Sivakumar K; Bien-Willner R; Flanigan KM; Sahenk Z; Barohn RJ; Walker CM; Mendell JR. 2010. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.  Annals Of Neurology. Vol. 67, no. 6. (June): e771.
  • Susman RD; Quijano-Roy S; Yang N; Webster R; Clarke NF; Dowling J; Kennerson M; Nicholson G; Biancalana V; Ilkovski B; Flanigan KM; Arbuckle S; Malladi C; Robinson P; Vucic S; Mayer M; Romero NB; Urtizberea JA; García-Bragado F; Guicheney P; Bitoun M; Carlier RY; North KN. 2010. Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy.  Neuromuscular Disorders: NMD. Vol. 20, no. 4. (April): e229.
  • Montanaro,Federica; Allen,Hugh,D; Mendell,Jerry,R; Kaspar,Rita,Wen; Flanigan,Kevin,M; Kissel,John,T; Pestronk,Alan; Weiss,Robert,B; Ray,Will; Alvarez,Carlos,E. 2010. Letter by Yilmaz et al Regarding Article, "Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy" Response.  CIRCULATION-CARDIOVASCULAR GENETICS. Vol. 3, no. 2. (April): E2-E2.
  • Kaspar RW; Allen HD; Ray WC; Alvarez CE; Kissel JT; Pestronk A; Weiss RB; Flanigan KM; Mendell JR; Montanaro F. 2009. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy.  Circulation. Cardiovascular Genetics. Vol. 2, no. 6. (December): e544.
  • Flanigan KM; Dunn DM; von Niederhausern A; Soltanzadeh P; Gappmaier E; Howard MT; Sampson JB; Mendell JR; Wall C; King WM; Pestronk A; Florence JM; Connolly AM; Mathews KD; Stephan CM; Laubenthal KS; Wong BL; Morehart PJ; Meyer A; Finkel RS; Bonnemann CG; Medne L; Day JW; Dalton JC; Margolis MK; Hinton VJ; Weiss RB. 2009. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort.  Human Mutation. Vol. 30, no. 12. (December): e1657.
  • Sato N; Amino T; Kobayashi K; Asakawa S; Ishiguro T; Tsunemi T; Takahashi M; Matsuura T; Flanigan KM; Iwasaki S; Ishino F; Saito Y; Murayama S; Yoshida M; Hashizume Y; Takahashi Y; Tsuji S; Shimizu N; Toda T; Ishikawa K; Mizusawa H. 2009. Spinocerebellar ataxia type 31 is associated with "inserted" penta-nucleotide repeats containing (TGGAA)n.  American Journal Of Human Genetics. Vol. 85, no. 5. (November): e544.
  • Flanigan KM; Dunn DM; von Niederhausern A; Howard MT; Mendell J; Connolly A; Saunders C; Modrcin A; Dasouki M; Comi GP; Del Bo R; Pickart A; Jacobson R; Finkel R; Medne L; Weiss RB. 2009. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy.  Neuromuscular Disorders: NMD. Vol. 19, no. 11. (November): e743.
  • Viollet L; Gailey S; Thornton DJ; Friedman NR; Flanigan KM; Mahan JD; Mendell JR. 2009. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy.  Muscle & Nerve. Vol. 40, no. 3. (September): e438.
  • Flanigan KM. 2009. Mutation-specific database and bioinformatics resource for DMD.  Human Mutation. Vol. 30, no. 6. (June): ev.
  • Gurvich OL; Maiti B; Weiss RB; Aggarwal G; Howard MT; Flanigan KM. 2009. DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6.  Human Mutation. Vol. 30, no. 4. (April): e633.
  • Butterfield RJ; Ramachandran D; Hasstedt SJ; Otterud BE; Leppert MF; Swoboda KJ; Flanigan KM. 2009. A novel form of juvenile recessive ALS maps to loci on 6p25 and 21q22.  Neuromuscular Disorders: NMD. Vol. 19, no. 4. (April): e279.
  • Maiti B; Arbogast S; Allamand V; Moyle MW; Anderson CB; Richard P; Guicheney P; Ferreiro A; Flanigan KM; Howard MT. 2009. A mutation in the SEPN1 selenocysteine redefinition element (SRE) reduces selenocysteine incorporation and leads to SEPN1-related myopathy.  Human Mutation. Vol. 30, no. 3. (March): e411.
  • Schessl J; Taratuto AL; Sewry C; Battini R; Chin SS; Maiti B; Dubrovsky AL; Erro MG; Espada G; Robertella M; Saccoliti M; Olmos P; Bridges LR; Standring P; Hu Y; Zou Y; Swoboda KJ; Scavina M; Goebel HH; Mitchell CA; Flanigan KM; Muntoni F; Bönnemann CG. 2009. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.  Brain: A Journal Of Neurology. Vol. 132, no. Pt 2. (February): e452.
  • Butterfield, R. J., D. Ramachandran, S. J. Hasstedt, B. E. Otterud, M. F. Leppert, K. J. Swoboda and K. M. Flanigan.2009. A novel form of juvenile recessive ALS maps to loci on 6p25 and 21q22. Neuromuscul Disord 19: 279-87. PubMed ID: 19318250
  • Flanigan, K. M., D. M. Dunn, A. von Niederhausern, P. Soltanzadeh, E. Gappmaier, M. T. Howard, J. B. Sampson, J. R. Mendell, C. Wall, W. M. King, A. Pestronk, J. M. Florence, A. M. Connolly, K. D. Mathews, C. M. Stephan, K. S. Laubenthal, B. L. Wong, P. J. Morehart, A. Meyer, 2009. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 30:1657-66. PubMed ID: 19937601
  • Gurvich, O. L., B. Maiti, R. B. Weiss, G. Aggarwal, M. T. Howard, and K. M. Flanigan. 2009. DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat 30: 633-40. PubMed ID: 19206170
  • Maiti, B., S. Arbogast, V. Allamand, M. W. Moyle, C. B. Anderson, P. Richard, P. Guicheney, A. Ferreiro, K. M. Flanigan, and M. T. Howard.2009. A mutation in the SEPN1 selenocysteine redefinition element (SRE) reduces selenocysteine incorporation and leads to SEPN1-related myopathy. Hum Mutat 30: 411-6. PubMed ID: 19067361
  • Flanigan, K. M., D. M. Dunn, A. von Niederhausern, M. T. Howard, J. Mendell, A. Connolly, C. Saunders, A. Modrcin, M. Dasouki, G. P. Comi, R. Del Bo, A. Pickart, R. Jacobson, R. Finkel, L. Medne, and R. B. Weiss. 2009. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord 19:743-8. PubMed ID: 19793655
  • Shprecher DR; Flanigan KM; Smith AG; Smith SM; Schenkenberg T; Steffens J. 2008. Clinical and diagnostic features of delayed hypoxic leukoencephalopathy.  The Journal Of Neuropsychiatry And Clinical Neurosciences. Vol. 20, no. 4. (September): e473.
  • Jurynec MJ; Xia R; Mackrill JJ; Gunther D; Crawford T; Flanigan KM; Abramson JJ; Howard MT; Grunwald DJ. 2008. Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle.  Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 105, no. 34. (August): e12485.
  • Bennett CL; Lawson VH; Brickell KL; Isaacs K; Seltzer W; Lipe HP; Weiss MD; Carter GT; Flanigan KM; Chance PF; Bird TD. 2008. Late-onset hereditary axonal neuropathies.  Neurology. Vol. 71, no. 1. (July): e14.
  • Lampe AK; Zou Y; Sudano D; O'Brien KK; Hicks D; Laval SH; Charlton R; Jimenez-Mallebrera C; Zhang RZ; Finkel RS; Tennekoon G; Schreiber G; van der Knaap MS; Marks H; Straub V; Flanigan KM; Chu ML; Muntoni F; Bushby KM; Bönnemann CG. 2008. Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance.  Human Mutation. Vol. 29, no. 6. (June): e809.
  • Bornstein B; Area E; Flanigan KM; Ganesh J; Jayakar P; Swoboda KJ; Coku J; Naini A; Shanske S; Tanji K; Hirano M; DiMauro S. 2008. Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene.  Neuromuscular Disorders: NMD. Vol. 18, no. 6. (June): e453.
  • Wagner KR; Fleckenstein JL; Amato AA; Barohn RJ; Bushby K; Escolar DM; Flanigan KM; Pestronk A; Tawil R; Wolfe GI; Eagle M; Florence JM; King WM; Pandya S; Straub V; Juneau P; Meyers K; Csimma C; Araujo T; Allen R; Parsons SA; Wozney JM; Lavallie ER; Mendell JR. 2008. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.  Annals Of Neurology. Vol. 63, no. 5. (May): e561.
  • Amiott EA; Lott P; Soto J; Kang PB; McCaffery JM; DiMauro S; Abel ED; Flanigan KM; Lawson VH; Shaw JM. 2008. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations.  Experimental Neurology. Vol. 211, no. 1. (May): e115.
  • Schessl J; Zou Y; McGrath MJ; Cowling BS; Maiti B; Chin SS; Sewry C; Battini R; Hu Y; Cottle DL; Rosenblatt M; Spruce L; Ganguly A; Kirschner J; Judkins AR; Golden JA; Goebel HH; Muntoni F; Flanigan KM; Mitchell CA; Bönnemann CG. 2008. Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy.  The Journal Of Clinical Investigation. Vol. 118, no. 3. (March): e904.
  • Gurvich, O.L., Tuohy, T.M., Howard, M.T., Finkel, R.S., Medne, L., Anderson, C.B., Weiss, R.B., Wilton, S.D., Flanigan, K.M. (2008) DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol., 2008 Jan;63(1):81-9. PubMed ID: 18059005
  • Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM. 2008. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.  Annals Of Neurology. Vol. 63, no. 1. (January): e81.
  • Eisenberg I; Eran A; Nishino I; Moggio M; Lamperti C; Amato AA; Lidov HG; Kang PB; North KN; Mitrani-Rosenbaum S; Flanigan KM; Neely LA; Whitney D; Beggs AH; Kohane IS; Kunkel LM. 2007. Distinctive patterns of microRNA expression in primary muscular disorders.  Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 104, no. 43. (October): e17016.
  • Reed PW; Corse AM; Porter NC; Flanigan KM; Bloch RJ. 2007. Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy.  Experimental Neurology. Vol. 205, no. 2. (June): e583.
  • Sampson JB; Smith SM; Smith AG; Singleton JR; Chin S; Pestronk A; Flanigan KM. 2007. Paraneoplastic myopathy: response to intravenous immunoglobulin.  Neuromuscular Disorders: NMD. Vol. 17, no. 5. (May): e404.
  • Jimenez-Mallebrera C; Maioli MA; Kim J; Brown SC; Feng L; Lampe AK; Bushby K; Hicks D; Flanigan KM; Bonnemann C; Sewry CA; Muntoni F. 2006. A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations.  Neuromuscular Disorders: NMD. Vol. 16, no. 9-10. (October): e571.
  • White SJ; Aartsma-Rus A; Flanigan KM; Weiss RB; Kneppers AL; Lalic T; Janson AA; Ginjaar HB; Breuning MH; den Dunnen JT. 2006. Duplications in the DMD gene.  Human Mutation. Vol. 27, no. 9. (September): e938.
  • Sampson JB; Chin SS; Clayton FC; Pestronk A; Swoboda KJ; Flanigan KM. 2006. An unusual pathologic feature associated with dermatomyositis.  Neuromuscular Disorders: NMD. Vol. 16, no. 6. (June): e391.
  • Reed P; Porter NC; Strong J; Pumplin DW; Corse AM; Luther PW; Flanigan KM; Bloch RJ. 2006. Sarcolemmal reorganization in facioscapulohumeral muscular dystrophy.  Annals Of Neurology. Vol. 59, no. 2. (February): e289.
  • Lawson VH; Graham BV; Flanigan KM. 2005. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene.  Neurology. Vol. 65, no. 2. (July): e197.
  • Howard MT; Aggarwal G; Anderson CB; Khatri S; Flanigan KM; Atkins JF. 2005. Recoding elements located adjacent to a subset of eukaryal selenocysteine-specifying UGA codons.  The EMBO Journal. Vol. 24, no. 8. (April): e1596.
  • Mercuri E; Lampe A; Allsop J; Knight R; Pane M; Kinali M; Bonnemann C; Flanigan K; Lapini I; Bushby K; Pepe G; Muntoni F. 2005. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy.  Neuromuscular Disorders: NMD. Vol. 15, no. 4. (April): e303.
  • Dent,K,M; Dunn,D,M; von Niederhausern,A,C; Aoyagi,A,T; Kerr,L; Bromberg,M,B; Hart,K,J; Tuohy,T; White,S; den Dunnen,J,T; Weiss,R,B; Flanigan,K,M. 2005. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort.  AMERICAN JOURNAL OF MEDICAL GENETICS PART A. Vol. 134A, no. 3. (April): 295-298.
  • Dent KM; Dunn DM; von Niederhausern AC; Aoyagi AT; Kerr L; Bromberg MB; Hart KJ; Tuohy T; White S; den Dunnen JT; Weiss RB; Flanigan KM. 2005. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort.  American Journal Of Medical Genetics. Part A. Vol. 134, no. 3. (April): e295.
  • Lampe AK; Dunn DM; von Niederhausern AC; Hamil C; Aoyagi A; Laval SH; Marie SK; Chu ML; Swoboda K; Muntoni F; Bonnemann CG; Flanigan KM; Bushby KM; Weiss RB. 2005. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy.  Journal Of Medical Genetics. Vol. 42, no. 2. (February): e108.
  • Lawson, V.H., Graham, B.V., and Flanigan, K.M. (2005) Clinical and electrophysiologic features of CMT2A with novel mutations in the Mfn2 Gene. Neurology, 65:197-204. PubMed ID: 16043786
  • Dent, K.M., Dunn, D.M., von Niederhausern, A.C., Aoyagi, A.T., Kerr, L., Bromberg, M.B., Tuohy, T., White, S., den Dunnen, J.T., Weiss, R.B., and Flanigan, K.M. (2005) Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genetics 134A:295-298.
    PubMed ID: 15723292
  • Howard, M.T., Aggarwal, G., Anderson, C.B., Khatri, S., Flanigan, K.M., Atkins, J.F. (2005) Recoding elements located adjacent to a subset of eukaryal selenocysteine-specifying UGA codons. EMBO J., Mar 24. PubMed ID: 15791204
  • Brockington M; Brown SC; Lampe A; Yuva Y; Feng L; Jimenez-Mallebrera C; Sewry CA; Flanigan KM; Bushby K; Muntoni F. 2004. Prenatal diagnosis of Ullrich congenital muscular dystrophy using haplotype analysis and collagen VI immunocytochemistry.  Prenatal Diagnosis. Vol. 24, no. 6. (June): e440.
  • Howard MT; Anderson CB; Fass U; Khatri S; Gesteland RF; Atkins JF; Flanigan KM. 2004. Readthrough of dystrophin stop codon mutations induced by aminoglycosides.  Annals Of Neurology. Vol. 55, no. 3. (March): e422.
  • Howard, M.T., Anderson, C.B., Fass, U., Khatri, S., Gesteland, R.F., Atkins, J.F., and Flanigan, K.M. (2004) Readthrough of dystrophin stop codon mutations induced by aminoglycoside compounds. Ann Neurol, Mar;55(3):422-426. PubMed ID: 10939566
  • Kevin M. Flanigan. 2004. Facioscapulohumeral Muscular Dystrophy and Scapuloperoneal Disorders. In Myology. 3 ed. Edited by Andrew G. Engel and Cara Franzini-Armstrong. New York: McGraw-Hill.
  • Walker AR; Tschetter K; Matsuo F; Flanigan KM. 2003. McArdle's disease presenting as recurrent cryptogenic renal failure due to occult seizures.  Muscle & Nerve. Vol. 28, no. 5. (November): e640.
  • Winokur ST; Chen YW; Masny PS; Martin JH; Ehmsen JT; Tapscott SJ; van der Maarel SM; Hayashi Y; Flanigan KM. 2003. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.  Human Molecular Genetics. Vol. 12, no. 22. (November): e2895.
  • Flanigan KM; von Niederhausern A; Dunn DM; Alder J; Mendell JR; Weiss RB. 2003. Rapid direct sequence analysis of the dystrophin gene.  American Journal Of Human Genetics. Vol. 72, no. 4. (April): e931.
  • Brockmann K; Pouwels PJ; Dechent P; Flanigan KM; Frahm J; Hanefeld F. 2003. Cerebral proton magnetic resonance spectroscopy of a patient with giant axonal neuropathy.  Brain & Development. Vol. 25, no. 1. (January): e45.
  • Brockmann, K., Pouwels, P.J., Dechent, P., Flanigan, K.M., Frahm, J., and Hanefeld, F. (2003) Cerebral proton magnetic resonance spectroscopy of a patient with giant axonal neuropathy. Brain Dev., Jan;25(1):45-50. PubMed ID: 12536033
  • Kevin M. Flanigan. 2003. Rigid Spine Syndrome. In Neuromuscular Diseases of Infancy, Childhood, and Adolescence. Edited by Jones HR, DeVivo D, Darras B. Philadelphia, PA: Butterworh-Heinemann.
  • Flanigan, K.M., von Niederhausern, A., Dunn, D., Alder, J., Mendell, J., and Weiss, R. (2003) Rapid Sequence Analysis of the Dystrophin Gene. American Journal of Human Genetics, 72:931-939. PubMed ID: 12632325
  • Winokur, S.T., Szabo, P.E., Chen, Y.-W., van der Maarel, S., Tapscott, S.J., Martin, J., Chung, S.-A., Ehmsen, J.T., and Flanigan, K.M. (2003) Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet., Nov 15;12(22):2895-2907.
    PubMed ID: 14519683
  • Flanigan KM; Coffeen CM; Sexton L; Stauffer D; Brunner S; Leppert MF. 2001. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy.  Neuromuscular Disorders: NMD. Vol. 11, no. 6-7. (September): e525.
  • Flanigan, K.M., Coffeen, C., Sexton, L., Brunner, S.L., Stauffer, D., and Leppert, M. (2001) Genetic Characterization of a Large, Historically Significant Utah Family with Facioscapulohumeral Dystrophy. Neuromuscular Disorders, 11:525-529. PubMed ID: 11525880
  • Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF. 2000. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.  Annals Of Neurology. Vol. 48, no. 2. (August): e164.
  • Flanigan KM. 2000. Genetic testing in the neuromuscular clinic.  Journal Of Clinical Neuromuscular Disease. Vol. 1, no. 4. (June): e205.
  • Coffeen CM; McKenna CE; Koeppen AH; Plaster NM; Maragakis N; Mihalopoulos J; Schwankhaus JD; Flanigan KM; Gregg RG; Ptácek LJ; Fu YH. 2000. Genetic localization of an autosomal dominant leukodystrophy mimicking chronic progressive multiple sclerosis to chromosome 5q31.  Human Molecular Genetics. Vol. 9, no. 5. (March): e787.
  • Flanigan KM; Kerr L; Bromberg MB; Leonard C; Tsuruda J; Zhang P; Gonzalez-Gomez I; Cohn R; Campbell KP; Leppert M. 2000. Congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological, and genetic study.  Annals Of Neurology. Vol. 47, no. 2. (February): e152.
  • Howard, M.T., Shirts, B H., Petros, L.M., Flanigan, K.M., Gesteland, R.F., and Atkins, J.F. (2000) Sequence Specificity of Aminoglycoside Induced Stop Codon Readthrough: Potential Implications for Treatment of Duchenne Muscular Dystrophy. Annals of Neurology, 48:164-169. PubMed ID: 10939566
  • Flanigan, K.M., Kerr, L., Bromberg, M.B., Leonard, C., Tsuruda, J., Zhang, P., Cohn, R., Campbell, K., and Leppert, M. (2000) Congenital Muscular Dystrophy with Rigid Spine Syndrome: A Clinical, Pathological, Radiologic, and Genetic Study. Annals of Neurology, 47(2):152-161. PubMed ID: 10665485
  • Plaster NM; Uyama E; Uchino M; Ikeda T; Flanigan KM; Kondo I; Ptácek LJ. 1999. Genetic localization of the familial adult myoclonic epilepsy (FAME) gene to chromosome 8q24.  Neurology. Vol. 53, no. 6. (October): e1180.
  • Flanigan, Kevin M. 1999. The Muscular Dystrophies: Update on Genetics and Appropriate Testing.  Neurologist. Vol. 5, no. 3. (May): 113-121.
  • Kevin M. Flanigan and Rajiv R. Ratan. 1999. Cell Death and the Mitochondrial Encephalomyopathies. In Cell Death and Diseases of the Nervous System. Edited by Vassilis E. Koliatsos and Rajiv R. Ratan. Totowa, New Jersy: Humana Press.
  • Flanigan KM; Bromberg MB; Gregory M; Baringer JR; Jones CR; Nester TA; Klatt EC; Townsend JJ. 1998. Calciphylaxis mimicking dermatomyositis: ischemic myopathy complicating renal failure.  Neurology. Vol. 51, no. 6. (December): e1634.
  • Flanigan KM; Lauria G; Griffin JW; Kuncl RW. 1998. Age-related biology and diseases of muscle and nerve.  Neurologic Clinics. Vol. 16, no. 3. (August): e659.
  • Meltzer CC; Wells SW; Becher MW; Flanigan KM; Oyler GA; Lee RR. 1998. AIDS-related MR hyperintensity of the basal ganglia.  AJNR. American Journal Of Neuroradiology. Vol. 19, no. 1. (January): e83.
  • Flanigan KM; Crawford TO; Griffin JW; Goebel HH; Kohlschütter A; Ranells J; Camfield PR; Ptácek LJ. 1998. Localization of the giant axonal neuropathy gene to chromosome 16q24.  Annals Of Neurology. Vol. 43, no. 1. (January): e143.
  • Flanigan, K.M., Crawford, T.O., Griffin, J., Goebel, H.H., Kohlschutter, A., Ranells, J., Camfield, P.R., and Ptacek, L.J. (1998) Localization of the Giant Axonal Neuropathy Gene to Chromosome 16q24. Annals of Neurology, 43(1):143-148. PubMed ID: 9450783
  • Ho TW; Hsieh ST; Nachamkin I; Willison HJ; Sheikh K; Kiehlbauch J; Flanigan K; McArthur JC; Cornblath DR; McKhann GM; Griffin JW. 1997. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection.  Neurology. Vol. 48, no. 3. (March): e717.
  • Scott,P; Barsan,W; Frederiksen,S; Kronick,S; Zink,B,J; Domeier,R,M; Mitchiner,J,C; JUDGE,F,P; Levy,R,J; Alexiou,A; Reincke,H; Segall,J,D; Walters,B; Swor,R; Gilroy,J; Goetting,M; Jackson,R; Richardson,D; Cisek,J; Randall,J; Schecter,S; Wilkinson,K; Walters,B,L; Adams,R; Carl,E; Nichols,F; Hess,D; Boop,B; Earley,C; Smith,D,R; Kaplan,P; Johnson,C; Morrow,C; Frohman,E; Porter,N; Flanigan,K; Morganstern,L; Holland,N; Stein,A; Aldrich,E; Oyler,G; Faught,E; Mitchell,V; Liu,H; Thomas,F; Wenzel,D; DAJANI,B,M; Pan,J,L; Yapundich,R; Futatsugi,Y; Geerlings,S; Moskowitz,T; Nicholas,A; Brockington,J; Collins,A; Bailey,J,M; Tseng,A; Koroshetz,W,J; Can,U; Felix,A; Cudkowticz,M; Buonanno,F; Schwamm,L; Elkind,M; Kistler,J,P; Finkelstein,S; Cha,J; Murphy,S; Blumenfeld,H; LOPEZBRESNAHAN,M; Can,U; GOSLIN,K; Cramer,S; Suwanwela,N; Homer,D; Carpenter,J; Wityk,R; Michel,N; Grufferman,S; Litt,B; Weiss,H; Guyot,A; Peterson,P; Tvardek,L; Schmidt,J; Deshpande,A; Freij,W; Gandhi,B; Minhas,F; Shah,J; Zahka,C; Penn,A; Sherman,J; Li,Y,L; Elleker,M,G; Stenerson,P; Brooke,H; AlJumah,M; AlAyafy,H; Pokroy,R; Hoppe,B; Pascuzzi,R; Farlow,M; Rightmyer,D; Bales,M; Caress,J; Pettigrew,C; Waugh,C; Rockich,A; Fallis,R; Tikhtman,A; Starkman,S; Schubert,G; Dobkin,B; Martin,N; Saver,J; Hanson,S; Weaver,A; PORTH,K; Magana,R; Davenport,J; Taylor,F; FREKING,D; HEROS,D,O; Schnek,E; Alter,M; Ribeiro,R; Lloyd,M; Scheiner,S; PUFF,A; Boyle,S; Gupta,N; White,K; Carney,S; Moulton,M; LaCapra,S; Hassard,D; Rizwan,S; Shah,A; NEWMARK,A; Gupta,A; Cone,D; Khan,I; Cohen,B; Bopari,R; OCONNELL,J; HUSSIAN,A; Patil,K; Shojari,J; Ribeiro,R; Bell,R; Gzech,D; MAZER,T; Grothusen,J; Reyes,P; Arastu,J; Strassburger,T; Thomas,C; Wolfe,R; Fang,J; Scavina,M; Wolfe,W; Zeidwerg,D; CHAVIN,J; Shachar,O; Sandler,L; McGarren,D; Jamieson,D,G; Gonnella,C; Bosley,T,M; Pollack,D,A; Andrefsky,J,C; Hariharan,S; Chang,A; Lamonte,M,P; Champellone,J; Hooker,H,C; Fellus,J; Sosa,V; RAAF,S; Friedman,M; BURCH,G; Atkins,D; Foley,C; Bivins,D; Elias,W; Nolan,D. 1996. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS).  STROKE. Vol. 27, no. 9. (September): 1453-1458.
  • Flanigan K; Gardner K; Alderson K; Galster B; Otterud B; Leppert MF; Kaplan C; Ptácek LJ. 1996. Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1.  American Journal Of Human Genetics. Vol. 59, no. 2. (August): e392.
  • Flanigan KM; Johns DR. 1993. Association of the 11778 mitochondrial DNA mutation and demyelinating disease.  Neurology. Vol. 43, no. 12. (December): e2720.
  • Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, Mendell JR, King WM, Pestronk A, Florence JM, Mathews KD, Finkel RS, Swoboda KJ, Gappmaier E, Howard MT, Day JW, McDonald C, McNally EM, Weiss RB; United Dystrophinopathy Project. LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy.  Ann Neurol.

Awards, Honors and Organizations

  • Listed, “Best Doctors in America”
Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000